KeyZell — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

KeyZell Biotech is a private, pre-clinical stage biopharmaceutical company pioneering a novel oncology therapeutic, LZ-167, supported by an AI-driven precision medicine platform. Founded in 2018 and headquartered in Seville, Spain, the company aims to initiate international clinical trials in 2024, targeting a significant unmet need in cancer care with a therapy designed for efficacy and reduced side effects. Backed by leadership with business and scientific expertise and recognized through awards like the Santander X Global Challenge, KeyZell is positioning itself as a potential disruptor in the global oncology market.

Oncology

Technology Platform

Proprietary artificial intelligence system for precision oncology, designed to analyze data and inform treatment decisions to support the development and application of its therapeutic candidate LZ-167.

Opportunities

The global oncology market is vast and growing, with a high demand for targeted therapies that reduce side effects.

KeyZell's AI-driven precision medicine approach could differentiate its therapy and improve success rates.

Its early international footprint provides a pathway to diverse clinical data and potential market access in both developed and emerging regions.

Risk Factors

The company faces high clinical development risk, as its lead asset has only preclinical data.

Executing four simultaneous international trials in 2024 presents significant operational and financial challenges.

As a pre-revenue company, it is dependent on raising capital in a competitive funding environment.

Competitive Landscape

KeyZell operates in the highly competitive oncology therapeutics sector, competing against large pharmaceutical companies and well-funded biotechs with advanced targeted therapies and immunotherapies. Its AI platform also places it against a growing field of digital health and computational biology companies. Success will require demonstrating superior efficacy, safety, or a unique predictive capability from its integrated platform.

More companies in Small Molecule Drugs →More companies in Spain →